Skip to content

LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT

LIVELUNG - Impact of CGA on QoL, Overall Survival and the Need for Admission in Patients Diagnosed With Localized NSCLC Treated With SBRT - a National Randomized Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05919641
Acronym
LIVELUNG
Enrollment
130
Registered
2023-06-26
Start date
2020-09-29
Completion date
2025-04-01
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Comprehensive Geriatric Assessment, Non-small Cell Lung Cancer, Stereotactic Body Radiotherapy

Keywords

NSCLC, SBRT, CGA

Brief summary

Older patients with non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) often die from other causes than lung cancer due to age-related comorbidities. This national randomized study will include 130 patients throughout 5 Danish cancer centres and investigate if a comprehensive geriatric intervention (CGA) when added upfront to SBRT for patients with localized NSCLC will have an impact on quality of life (QoL), overall survival, physical functionality and unplanned hospital admissions. If an upfront CGA improves patients' general health status, this study could lead to implementation of a CGA in standard clinical practice as well as further research on older patients receiving radiotherapy.

Interventions

OTHERComprehensive Geriatric Assessment

Comprehensive geriatric assessment (CGA) is defined as a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional capabilities of an older adult in order to develop a coordinated plan to maximize overall health with aging.

Sponsors

Odense University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with cytologically or histologically proven non-small cell lung cancer * Stage T1-3N0M0 * ≥ 70 years old * In a multidisciplinary setting the patient is considered medically inoperable, too frail for operation due to age and/or comorbidity or that the patient refuse surgery and therefore candidate for SBRT.

Exclusion criteria

* Missing histology/cytology * Another current malignancy * Higher staging at treatment planning * Not able to provide informed consent * Do not speak or understand Danish

Design outcomes

Primary

MeasureTime frameDescription
Quality of Life (EQ-5D)12 monthsQuestionnaire with 5 dimensions each with 5 (1-5) levels representing the health status of the patient and the patients self-rated health status on a scale from 0-100 (EQ VAS). The score of the 5 dimensions can be converted into a single index value 0-1 with higher values indicating poorer health status.

Secondary

MeasureTime frameDescription
Quality of Life (EQ-5D)3 monthsQuestionnaire with 5 dimensions each with 5 (1-5) levels representing the health status of the patient and the patients self-rated health status on a scale from 0-100 (EQ VAS). The score of the 5 dimensions can be converted into a single index value 0-1 with higher values indicating poorer health status.
Hand-grip strength12 monthsHand-grip strength measured in kilo using a JAMAR hand dynamometer
Overall Survival (OS)12 monthsThe time from treatment to death, regardless of disease recurrence
Chair-stand-test (CST)12 monthsThe CST involves recording the number of stands from a chair a person can complete in 30 seconds
Unplanned Admissions12 monthsTime to first unplanned admission
Timed-up-and-go (TUG)12 monthsTUG consists of timing (seconds) a patient getting up from a chair from the sitting to the bipedal position, walking three meters, turning, returning, and sitting on the chair again

Countries

Denmark

Contacts

Primary ContactKristian K Bentsen, Dr.med.
kristian.kirkelund.bentsen3@rsyd.dk004528735210
Backup ContactStefan S Jeppesen, Dr.med
Stefan.Jeppesen@rsyd.dk004530502948

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026